Sen. Ron Wyden Sells Solventum Co. (NYSE:SOLV) Stock

Senator Ron Wyden (D-Oregon) recently sold shares of Solventum Co. (NYSE:SOLV). In a filing disclosed on February 21st, the Senator disclosed that they had sold between $1,001 and $15,000 in Solventum stock on February 6th.

Senator Ron Wyden also recently made the following trade(s):

• Sold $50,001 – $100,000 in shares of Eli Lilly and Company (NYSE:LLY) on 2/10/2025.
• Sold $1,001 – $15,000 in shares of iRobot (NASDAQ:IRBT) on 2/6/2025.
• Purchased $50,001 – $100,000 in shares of Eli Lilly and Company (NYSE:LLY) on 1/22/2025.

Solventum Stock Down 1.9 %

SOLV stock opened at $73.08 on Friday. The company has a debt-to-equity ratio of 2.45, a quick ratio of 0.83 and a current ratio of 1.15. Solventum Co. has a 52-week low of $47.16 and a 52-week high of $96.05. The company has a 50-day moving average of $71.14 and a two-hundred day moving average of $69.07.

Institutional Inflows and Outflows

A number of large investors have recently made changes to their positions in the stock. Worldquant Millennium Advisors LLC raised its position in Solventum by 373.6% in the third quarter. Worldquant Millennium Advisors LLC now owns 47,665 shares of the company’s stock worth $3,323,000 after purchasing an additional 37,600 shares in the last quarter. Harbor Capital Advisors Inc. raised its position in Solventum by 24.8% in the fourth quarter. Harbor Capital Advisors Inc. now owns 46,965 shares of the company’s stock worth $3,103,000 after purchasing an additional 9,333 shares in the last quarter. The Manufacturers Life Insurance Company raised its position in Solventum by 37.4% in the third quarter. The Manufacturers Life Insurance Company now owns 117,853 shares of the company’s stock worth $8,217,000 after purchasing an additional 32,051 shares in the last quarter. State Street Corp raised its position in Solventum by 3.1% in the third quarter. State Street Corp now owns 6,107,550 shares of the company’s stock worth $425,818,000 after purchasing an additional 185,938 shares in the last quarter. Finally, Forsta AP Fonden acquired a new position in Solventum in the fourth quarter worth about $1,876,000.

Analyst Ratings Changes

A number of research firms have issued reports on SOLV. Piper Sandler upped their price target on shares of Solventum from $71.00 to $75.00 and gave the company a “neutral” rating in a report on Friday, November 8th. Mizuho began coverage on shares of Solventum in a report on Wednesday, December 4th. They set a “neutral” rating and a $70.00 price target for the company. Finally, Morgan Stanley upped their price target on shares of Solventum from $60.00 to $73.00 and gave the company an “equal weight” rating in a report on Monday, November 11th. One research analyst has rated the stock with a sell rating, nine have given a hold rating and one has given a buy rating to the company. According to MarketBeat, the stock presently has an average rating of “Hold” and a consensus price target of $68.29.

About Senator Wyden

Ron Wyden (Democratic Party) is a member of the U.S. Senate from Oregon. He assumed office on January 30, 1996. His current term ends on January 3, 2029. Wyden (Democratic Party, Independent Party) ran for re-election to the U.S. Senate to represent Oregon. He won in the general election on November 8, 2022. He advanced from the Democratic primary on May 17, 2022. In 2018, the Town Hall Project, which described itself as “a citizen powered, grassroots effort that empowers constituents across the country to have face-to-face conversations with their elected representatives,” named Wyden town hall MVP for the second year in a row. According to OregonLive, Wyden held over 900 town hall meetings between 1996 and 2018. Wyden previously served in the U.S. House of Representatives, representing Oregon’s 3rd Congressional District from 1981 to 1996. As of a 2014 analysis of multiple outside rankings, Wyden is an average Democratic member of Congress, meaning he will vote with the Democratic Party on the majority of bills.

Solventum Company Profile

Solventum Corporation, a healthcare company, engages in the developing, manufacturing, and commercializing a portfolio of solutions to address critical customer and patient needs. It operates through four segments: Medsurg, Dental Solutions, Health Information Systems, and Purification and Filtration.